Acadian Asset Management LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Acadian Asset Management LLC increased its stake in Pfizer Inc. by 11.7% during the first quarter, owning a total of 676,698 shares valued at $17.14 million.
• Pfizer's recent earnings report showed $0.78 earnings per share, exceeding analyst expectations, with a 10.3% year-over-year revenue increase to $14.65 billion.
• The company declared a quarterly dividend of $0.43 per share, yielding 6.9%, and has an anticipated EPS for FY 2025 set between 2.90 and 3.10.

Acadian Asset Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 676,698 shares of the biopharmaceutical company's stock after purchasing an additional 70,847 shares during the quarter. Acadian Asset Management LLC's holdings in Pfizer were worth $17,141,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Geneos Wealth Management Inc. increased its holdings in Pfizer by 8.5% in the 1st quarter. Geneos Wealth Management Inc. now owns 59,158 shares of the biopharmaceutical company's stock worth $1,499,000 after acquiring an additional 4,614 shares in the last quarter. Bluefin Capital Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at about $441,000. Acorns Advisers LLC grew its position in shares of Pfizer by 10.5% in the first quarter. Acorns Advisers LLC now owns 9,416 shares of the biopharmaceutical company's stock valued at $239,000 after purchasing an additional 893 shares during the period. Blue Rock Wealth Management LLC acquired a new stake in shares of Pfizer in the first quarter valued at about $325,000. Finally, Focus Partners Wealth grew its position in shares of Pfizer by 14.5% in the first quarter. Focus Partners Wealth now owns 1,502,189 shares of the biopharmaceutical company's stock valued at $38,066,000 after purchasing an additional 190,288 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.1%

Shares of PFE opened at $24.84 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a 50-day moving average price of $24.82 and a 200 day moving average price of $24.32. The firm has a market capitalization of $141.23 billion, a P/E ratio of 13.21, a P/E/G ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date was Friday, July 25th. Pfizer's payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on PFE shares. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Bank of America lifted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.